Drug Overview
Aggrenox (Boehringer Ingelheim/GlaxoSmithKline/Bayer) capsules contain two active ingredients, acetylsalicylic acid and extend-release dipyridamole. Each active ingredient inhibits platelet aggregation through a distinct pathway. Aspirin works by irreversibly inhibiting the cyclooxygenase-1 and cyclooxygenase-2 enzymes, which are responsible for the synthesis of prostaglandins and thromboxanes.
Prostaglandins and thromboxanes trigger the platelet aggregation needed for clot formation to occur. By inhibiting cyclooxygenase-1 and cyclooxygenase-2, Aspirin decreases the number of prostaglandins and thromboxanes present, resulting in a reduction in platelet aggregation. By limiting platelet aggregation, Aspirin inhibits blood clot formation.
Aggrenox (Boehringer Ingelheim/GlaxoSmithKline/Bayer) capsules contain two active ingredients, acetylsalicylic acid and extend-release dipyridamole. Each active ingredient inhibits platelet aggregation through a distinct pathway. Aspirin works by irreversibly inhibiting the cyclooxygenase-1 and cyclooxygenase-2 enzymes, which are responsible for the synthesis of prostaglandins and thromboxanes.
Prostaglandins and thromboxanes trigger the platelet aggregation needed for clot formation to occur. By inhibiting cyclooxygenase-1 and cyclooxygenase-2, Aspirin decreases the number of prostaglandins and thromboxanes present, resulting in a reduction in platelet aggregation. By limiting platelet aggregation, Aspirin inhibits blood clot formation.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
